24 / 27
Higher benefit in patients treated in FIRST-line
Results
•
Efficacy
data after a median follow-up of 7 months (range, 0.4–14.6) of treatment initiation with LEN.
Outcome
Lenvatinib (n=75)
Best overall response (BOR), n (%)*
CR
PR
SD
PD
NE
23 (31)
0
23 (31)
38 (51)
4 (5)
10 (13)
Median time to BOR, mo (range)
3 (0.4 - 1.7)
BOR according to Treatment Line, n (%)*
1L PR / SD / PD
2L+ PR / SD / PD
10 (42) / 12 (50) / 0 (0)
13 (25) / 26 (51) / 4 (8)
Median PFS, mo (95% CI)
10 (NA)
Median OS, mo (95% CI)
NE (NA)
*Measured according to RECIST v1.1.
•
The inferior overall response rates and PFS from this real-life study in
patients that were sicker and
more heavily pre-treated
than in the previous phase 2 and phase 3 trials, suggest that Lenvatinib
treatment should be initiated
when patients are still in good general condition with a limited
tumour burden to take full advantage of its efficacy
.
Berdelou A, et al. Thyroid. 2017